Fennec Pharmaceuticals (FENC) Q4 2025 earnings review
Surging Revenue Meets Aggressive Reinvestment
Fennec's growth engine is officially firing on all cylinders. Q4 net product sales surged 75% YoY to $13.8M, marking the fifth consecutive quarter of sequential growth. The company successfully executed a $42M equity raise, completely eliminated its debt, and settled a major patent dispute with Cipla, clearing the runway for PEDMARK through 2033. However, this top-line acceleration comes with a steep near-term cost: management is guiding for 2026 cash operating expenses to surge to $50M as they aggressively expand the commercial team. Fennec is consciously choosing to push out profitability to capture the vast Adolescent and Young Adult (AYA) market—a bold but mathematically sound bet to maximize PEDMARK's peak sales.
🐂 Bull Case
The 75% YoY jump in Q4 sales proves the AYA market thesis is working. Conversion rates hit an all-time high of 70% in Q4 (up from 50% in Q1), driven by the Fennec HEARS patient support program.
The company ended the year with $36.8M in cash and zero debt. Crucially, the Cipla patent settlement removes the generic threat until late 2033, ensuring long-term pricing power and exclusivity.
🐻 Bear Case
With cash operating expenses jumping ~43% to $50M in 2026, the company's path to cash-flow breakeven requires significantly higher revenue thresholds, ensuring elevated cash burn in the near term.
The massive OpEx hike is directly tied to expanding the sales force. If the new reps fail to efficiently penetrate highly fragmented community oncology centers, margins will compress severely.
⚖️ Verdict: 🟢
Bullish. The top-line momentum is undeniable. Eliminating both the debt burden and the generic threat fundamentally de-risks the investment story. While the $50M OpEx guide is a heavy near-term anchor, it is a necessary investment to unlock the lucrative AYA market.
Key Themes
AYA Market Penetration Accelerating
The Adolescent and Young Adult (AYA) market continues to be Fennec's primary growth engine. Management noted record patient enrollments, infused vials, and active patients in Q4. The Fennec HEARS program is successfully removing access friction, evidenced by conversion rates jumping from 50% in Q1 2025 to 70% in Q4. This demonstrates that physicians are moving past initial trials into repeat, high-frequency prescribing.
Steeper Climb to Breakeven via OpEx Surge
The company's decision to rapidly expand its customer-facing teams will cause cash operating expenses to jump from ~$35M in 2025 to ~$50M in 2026. This reversing trend in cost discipline means the previous breakeven target (which required $8.5M-$9M in quarterly sales) is no longer valid. Management explicitly stated that the new hires will not make material revenue contributions until the second half of 2026, creating a margin trough in H1 2026.
Resolution of Major Financial and Legal Overhangs
Fennec systematically cleaned up its risk profile in Q4. The company deployed proceeds from a $42M equity raise to pay off $21.5M in debt, exiting the year debt-free. More importantly, the settlement with Cipla ensures no generic sodium thiosulfate entry until September 1, 2033. This not only protects the revenue tail but will save 'multiple millions' in annual legal G&A expenses going forward.
European Expansion Maturing via Norgine
Following launches in the U.K. and Germany, partner Norgine secured approval in Switzerland and is planning 8 to 10 additional European country launches in 2026. Management expects Norgine's royalty contributions to become a material driver to Fennec's financials in the second half of 2026, alongside potential milestones tied to final German pricing expected mid-year.
Expanding Clinical Evidence Base in Adults
Fennec is aggressively broadening PEDMARK's applicability beyond pediatrics. New retrospective data presented at MHNCS demonstrated safe administration in 15 adults with Head and Neck Cancers (HNC). Furthermore, City of Hope initiated a study for stage II-III metastatic testicular germ cell tumors, and Tampa General Hospital initiated a real-world utility study for AYA and adult cancer patients. This institution-led research is vital for future guideline inclusion.
Other KPIs
Stable. Management noted they expect a clean P&L in 2026 with gross-to-net drop down remaining at approximately 85% of gross sales to net sales. This indicates that despite pushing into new territories and community clinics, Fennec is not sacrificing pricing power or suffering from deteriorating payer pushback.
Reversing. Operating loss widened from $(0.9)M in 24Q4, driven heavily by G&A expenses doubling to $8.9M and S&M increasing to $6.1M. This reflects the front-loaded costs of expanding the commercial footprint and IP legal fees incurred before the recent Cipla settlement.
Guidance
Accelerating. This represents a ~43% increase from FY25's ~$35 million. Management noted that spending will be front-loaded, with over 60% of total cash OpEx occurring in the first half of calendar 2026 as the commercial expansion rolls out.
Stable. Fennec expects Cost of Goods Sold to remain firmly in the mid-single digits as a percentage of revenue, preserving an elite 90%+ gross margin profile to help absorb the massive SG&A investments.
Key Questions
Breakeven Revenue Threshold
With the 2026 cash OpEx guide stepping up to $50 million, what is the new quarterly revenue run-rate required to achieve cash flow breakeven, and is that achievable before Q4 2026?
Sales Force ROI
You noted the expanded sales team won't materially contribute until H2 2026. What specific leading indicators—such as new account activations or prescriptions written—are you tracking to ensure this $15M incremental investment is yielding the expected ROI?
Japan Regulatory Timeline
With positive topline data from the STS-J01 trial now in hand, what is the expected timeline for submitting a regulatory dossier in Japan, and do you intend to sign a commercial partner prior to submission?